Contrasting the roles of costimulation and the natural adjuvant lipopolysaccharide during the induction of T cell immunity

被引:32
作者
Maxwell, JR
Ruby, C
Kerkvliet, NI
Vella, AT
机构
[1] Univ Connecticut, Ctr Hlth, Dept Immunol, Div Immunol, Farmington, CT 06030 USA
[2] Oregon State Univ, Dept Microbiol, Corvallis, OR 97331 USA
[3] Oregon State Univ, Dept Toxicol, Corvallis, OR 97331 USA
关键词
D O I
10.4049/jimmunol.168.9.4372
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The requirements for circumventing tolerance induction in favor of memory T cell development are poorly understood. Although two signals (Ag and costimulation) are necessary to drive effective T cell clonal expansion, few memory T cells remain after the response wanes. The adjuvant LPS can increase numbers of long-lived Ag-specific T cells, but its mechanism of action is not understood. In this report, it is shown that LPS, when combined with two-signal stimulation, profoundly enhances T cell survival in vivo. This survival does not appear to be dependent on the cytokines TNF-alpha, IL-1beta, IL-6, and IFN-gamma, nor is it dependent on the transcription factor NF-kappaB. However, in vivo proliferation of NF-kappaB-deficient T cells was comparable to that of wild-type T cells, yet their early accumulation in the lymph nodes was severely reduced unless the mice were treated with LPS and an agonistic CD40 mAb. Most importantly, we found that activation of two different costimulatory signals, CD-l0 and OX40, could not substitute for LPS in rescuing T cells from peripheral deletion. Perhaps surprisingly, these data show that LPS delivers a qualitatively different signal than multiple costimulatory signals.
引用
收藏
页码:4372 / 4381
页数:10
相关论文
共 70 条
[1]   STRATEGIES OF ANTICYTOKINE MONOCLONAL-ANTIBODY DEVELOPMENT - IMMUNOASSAY OF IL-10 AND IL-5 IN CLINICAL-SAMPLES [J].
ABRAMS, JS ;
RONCAROLO, MG ;
YSSEL, H ;
ANDERSSON, U ;
GLEICH, GJ ;
SILVER, JE .
IMMUNOLOGICAL REVIEWS, 1992, 127 :5-24
[2]   CD40 EXPRESSION BY HUMAN MONOCYTES - REGULATION BY CYTOKINES AND ACTIVATION OF MONOCYTES BY THE LIGAND FOR CD40 [J].
ALDERSON, MR ;
ARMITAGE, RJ ;
TOUGH, TW ;
STROCKBINE, L ;
FANSLOW, WC ;
SPRIGGS, MK .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (02) :669-674
[3]  
Aune TM, 1999, J IMMUNOL, V162, P5805
[4]   Interleukin-6 (IL-6) prevents activation-induced cell death: IL-2-independent inhibition of Fas/fasL expression and cell death [J].
Ayroldi, E ;
Zollo, O ;
Cannarile, L ;
D' Adamio, FD ;
Grohmann, U ;
Delfino, DV ;
Riccardi, C .
BLOOD, 1998, 92 (11) :4212-4219
[5]  
BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141
[6]   I-KAPPA-B - A SPECIFIC INHIBITOR OF THE NF-KAPPA-B TRANSCRIPTION FACTOR [J].
BAEUERLE, PA ;
BALTIMORE, D .
SCIENCE, 1988, 242 (4878) :540-546
[7]   Apoptosis: Activate NF-kappa B or die? [J].
Baichwal, VR ;
Baeuerle, PA .
CURRENT BIOLOGY, 1997, 7 (02) :R94-R96
[8]   The NF-kappa B and I kappa B proteins: New discoveries and insights [J].
Baldwin, AS .
ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 :649-683
[9]   Mechanisms of disease - Nuclear factor-kappa b - A pivotal transcription factor in chronic inflammatory diseases [J].
Barnes, PJ ;
Larin, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (15) :1066-1071
[10]   An essential role for NF-kappa B in preventing TNF-alpha-induced cell death [J].
Beg, AA ;
Baltimore, D .
SCIENCE, 1996, 274 (5288) :782-784